Skip to main content

Table 5 Summary of multivariable regression results of type 2 diabetes patients treated with lixisenatide add-on treatment to basal insulin therapy ± oral antidiabetic drugs placed in different body mass index (BMI) groups based on their baseline BMI

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

 

Estimated difference

95 % Confidence limits

P-value

Lower

Upper

Change in HbA1c (%)

    

 BMI <25 kg/m2 vs. BMI ≥35 kg/m2

0.32

0.10

0.53

0.005

 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2

0.09

−0.09

0.26

0.32

 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2

−0.01

−0.18

0.17

0.94

 

Odds ratio

Lower

Upper

p-value

Endpoint HbA1c <7 %

 BMI <25 kg/m2 vs. BMI ≥35 kg/m2

0.48

0.27

0.86

0.014

 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2

0.59

0.37

0.92

0.020

 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2

0.82

0.52

1.30

0.40

Endpoint HbA1c <7 % and no weight gain

 BMI <25 kg/m2 vs. BMI ≥35 kg/m2

0.47

0.26

0.88

0.018

 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2

0.72

0.45

1.15

0.17

 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2

0.79

0.49

1.29

0.35

HbA1c <7 %, no severe hypoglycemia, and no weight gain

 BMI <25 kg/m2 vs. BMI ≥35 kg/m2

0.47

0.26

0.88

0.018

 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2

0.72

0.45

1.15

0.17

 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2

0.79

0.49

1.29

0.35